[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100239354":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":10,"locations":10,"responsibleParty":28,"collaborators":30,"id":34,"slug":35,"hasResults":36,"nctId":37,"briefTitle":38,"officialTitle":39,"acronym":40,"eligibilityCriteria":41,"healthyVolunteers":36,"sex":42,"minAge":10,"maxAge":10,"enrollmentInfo":43,"targetDuration":10,"studyType":46,"phases":10,"briefSummary":47,"conditions":48,"keywords":50,"overallStatus":52,"whyStopped":10,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":10},{"fullName":5,"class":6},"Grupo Español de Investigación en Cáncer de Ovario","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Trabectedin+ PLD",null,"Trabectedin and Pegylated Liposomal Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), according to SmPC.",[13],"Drug: Trabectedin and Pegylated Liposomal Doxorubicin",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DRUG","Trabectedin and Pegylated Liposomal Doxorubicin","Trabectedin and Pegylated Liposomal Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), according to SmPC from October 28, 2009 to October 31, 2014",[9],[21,25],{"name":22,"affiliation":23,"role":24},"Laura Vidal, MD","H. Clinic, Barcelona","PRINCIPAL_INVESTIGATOR",{"name":26,"affiliation":27,"role":24},"Jose M Del Campo, MD","H. Vall d'Hebron, Barcelona",{"type":29,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[31],{"name":32,"class":33},"PharmaMar","INDUSTRY","100239354","retrospective-study-to-analyze-the-efficacy-and-safety-of-trabectedin-and-pegylated-liposomal-doxorubicin-pld--in-the-treatment-of-patients-with-platinum-sensitive-recurrent-ovarian-cancer-roc-according-to-smpc-100239354",false,"NCT02394015","Retrospective Study to Analyze the Efficacy and Safety of Trabectedin and Pegylated Liposomal Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), According to SmPC","Multicenter and Retrospective Observational Study to Analyze the Efficacy and Safety of the Combination With Trabectedin and Pegylated Liposomal Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), According to Data Sheet","RETRO-ROC","Inclusion Criteria:\n\n* Patients who have received at least one dose of trabectedin - doxorubicin pegylated for recurrent ovarian cancer according to SMPC, between October 28, 2009 and October 31, 2014 and which have not been included in clinical trials where the IMP was trabectedin.\n\nExclusion Criteria:\n\n* Patients with records unavailable (lost, empty or not recoverable).","FEMALE",{"count":44,"type":45},90,"ACTUAL","OBSERVATIONAL","Retrospective Study to Analyze the Efficacy and Safety of Trabectedin and Pegylated Liposomal Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), According to SmPC.",[49],"Ovarian Epithelial Cancer Recurrent",[51],"Platinum-sensitive Recurrent Ovarian Cancer","COMPLETED","2020-03-26",{"date":55,"type":45},"2020-03-27",{"date":57,"type":45},"2013-05-06",{"date":59,"type":45},"2017-12",{"name":5,"class":6}]